Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease

Trial Profile

Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 04 Mar 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 17 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top